Weekly TechBio News 🍊
📙Juvenescence Acquires Ro5
Juvenescence, a biotech company focused on longevity and age-related diseases, just acquired Ro5, an AI-driven drug discovery startup (Juvenescence Acquires Ro5 to Integrate AI and Machine Learning in Drug Discovery), in a move aimed at strengthening its artificial intelligence and machine learning capabilities in drug discovery and development. Ro5 provides support for each individual stage of the drug discovery process for pharma, biotech, and academic institutions with it's Ro5's AI platforms.
▶️ Back on May 21, 2025, Juvenescence raised 💲7️⃣6️⃣M led by M42, a health-tech investment group based in Abu Dhabi (Juvenescence Secures $76M in Series B-1 Financing Led by M42 to Accelerate AI-Driven Drug Development). Juvenescence Limited is a British Virgin Islands-based holding company that invests in human aging and longevity.
Use of Funds:
Expand its portfolio of AI-developed therapeutics targeting aging and age-related diseases.
Advance preclinical and clinical programs including PAI-1 Inhibitor (fibrosis), GDF-15 mAb (muscle wasting), CD38 Inhibitor (rheumatoid arthritis), Ketone Rx (heart failure), and Plasmalogen (alzheimer's disease).